Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Impedimed Limited ( (AU:IPD) ) has shared an announcement.
ImpediMed Limited has announced it will release its Quarterly Cash Flow Report for the period ending December 31, 2024, on January 31, 2025. The company will also host an investor conference call on the same day led by CEO Dr. Parmjot Bains and CF&OO McGregor Grant, providing stakeholders an opportunity to engage with leadership and discuss the company’s financial performance, which could influence investor confidence and impact market positioning.
More about Impedimed Limited
ImpediMed Limited is an Australian company operating in the medical technology industry, focusing on the development of non-invasive medical devices designed to measure, monitor, and manage fluid status and body composition using bioimpedance spectroscopy.
YTD Price Performance: 11.11%
Average Trading Volume: 30,860
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.99M
See more insights into IPD stock on TipRanks’ Stock Analysis page.
